UBS AM
LAB icon

UBS AM’s Standard BioTools LAB Stock Holding History

UBS AM’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-519,783
Closed -$478K – 3813
2026
Q1 		$478K Hold
519,783
– – ﹤0.01% 2566
2025
Q4 		$665K Buy
519,783
+7,075
+1% +$9.51K ﹤0.01% 2263
2025
Q3 		$667K Sell
512,708
-230,964
-31% -$303K ﹤0.01% 2115
2025
Q2 		$892K Buy
743,672
+189,469
+34% +$210K ﹤0.01% 2415
2025
Q1 		$599K Hold
554,203
– – ﹤0.01% 2460
2024
Q4 		$970K Buy
554,203
+247,332
+81% +$461K ﹤0.01% 2372
2024
Q3 		$592K Sell
306,871
-75,617
-20% -$148K ﹤0.01% 2603
2024
Q2 		$677K Buy
382,488
+278,428
+268% +$681K ﹤0.01% 2544
2024
Q1 		$282K Buy
+104,060
New +$251K ﹤0.01% 2408
2022
Q2 		– Sell
-82,974
Closed -$298K – 2732
2022
Q1 		$298K Hold
82,974
– – ﹤0.01% 2597
2021
Q4 		$325K Sell
82,974
-9,425
-10% -$44.1K ﹤0.01% 2663
2021
Q3 		$609K Sell
92,399
-30,320
-25% -$199K ﹤0.01% 2418
2021
Q2 		$756K Buy
122,719
+15,819
+15% +$84.6K ﹤0.01% 2355
2021
Q1 		$483K Sell
106,900
-8,400
-7% -$46.1K ﹤0.01% 2402
2020
Q4 		$692K Buy
+115,300
New +$757K ﹤0.01% 2166
2020
Q2 		– Sell
-67,850
Closed -$172K – 2503
2020
Q1 		$172K Buy
67,850
+24,947
+58% +$82K ﹤0.01% 2318
2019
Q4 		$149K Sell
42,903
-5,360
-11% -$18.9K ﹤0.01% 2495
2019
Q3 		$223K Buy
48,263
+5,336
+12% +$42K ﹤0.01% 2545
2019
Q2 		$529K Buy
+42,927
New +$547K ﹤0.01% 2185
2016
Q1 		– Sell
-10,099
Closed -$109K – 2647
2015
Q4 		$109K Hold
10,099
– – ﹤0.01% 2650
2015
Q3 		$82K Hold
10,099
– – ﹤0.01% 2629
2015
Q2 		$244K Buy
10,099
+300
+3% +$9.47K ﹤0.01% 2491
2015
Q1 		$413K Buy
9,799
+500
+5% +$19.8K ﹤0.01% 2086
2014
Q4 		$314K Buy
+9,299
New +$263K ﹤0.01% 2204
2014
Q3 		– Sell
-7,999
Closed -$235K – 2576
2014
Q2 		$235K Hold
7,999
– – ﹤0.01% 2323
2014
Q1 		$353K Buy
7,999
+1,200
+18% +$52.8K ﹤0.01% 2080
2013
Q4 		$261K Sell
6,799
-4,000
-37% -$118K ﹤0.01% 2221
2013
Q3 		$237K Hold
10,799
– – ﹤0.01% 2231
2013
Q2 		$189K Buy
+10,799
New +$190K ﹤0.01% 2284

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

UBS AM's LAB Position: Q2 2026 in Review

UBS AM sold out of Standard BioTools (LAB) in Q2 2026, closing a stake of 519,783 shares — an estimated $478K sold.

UBS AM first reported a position in LAB in Q2 2013 and held it in 29 quarters. The position peaked at $970K in Q4 2024. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • UBS AM reported no remaining Standard BioTools position as of Q2 2026 after selling out during the quarter.
  • UBS AM sold 519,783 Standard BioTools shares in Q2 2026, an estimated $478K.
  • UBS AM first reported a position in Standard BioTools in Q2 2013 and held it in 29 quarters.
  • UBS AM's Standard BioTools position peaked at $970K in Q4 2024.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.